Hospital
Clallam County Public Hospital District 2
Clallam County Public Hospital District 2 was paid $68.86M by Medicaid between Jan 2018 and Dec 2024, across 438 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 15% of everything it billed.
33Billing provider infoCLALLAM COUNTY PUBLIC HOSPITAL DISTRICT 2
PORT ANGELES, WA 98362
PORT ANGELES, WA 98362
33aNPI1306845557assigned 07/19/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$68.86M
24GClaims1,526,308
24DCodes billed438
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Washington
Rank by total paid#7 of 49
Median peer was paid$20.06M
This provider vs. median3.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 196,781 | $9.11M | |
| 2019 | 220,686 | $10.31M | |
| 2020 | 202,903 | $9.22M | |
| 2021 | 236,486 | $10.81M | |
| 2022 | 235,295 | $11.16M | |
| 2023 | 239,796 | $9.83M | |
| 2024incomplete | 194,361 | $8.42M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 15% | 66,087 | 58,993 | $10.11M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 15% | 63,254 | 53,713 | $10.08M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 15% | 89,545 | 69,205 | $10.06M |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.9% | 7,624 | 5,708 | $2.67M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.4% | 19,934 | 18,021 | $2.33M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.0% | 15,441 | 14,310 | $2.09M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.7% | 13,126 | 8,584 | $1.88M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.7% | 23,634 | 21,796 | $1.86M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.4% | 18,210 | 16,166 | $1.65M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.3% | 11,430 | 10,683 | $1.61M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 6,456 | 6,166 | $1.38M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.9% | 9,379 | 6,481 | $1.32M |
426 more codes
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.8% | 4,364 | $1.22M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.3% | 5,795 | $906K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.2% | 18,996 | $832K |
| 59025 | Fetal non-stress test | 1.1% | 3,716 | $789K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 2,629 | $741K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 34,789 | $674K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 4,322 | $522K |
| 20610 | <1% | 2,727 | $465K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,264 | $455K |
| 80053 | Comprehensive metabolic panel | <1% | 69,563 | $449K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 11,456 | $446K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,675 | $420K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,188 | $410K |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 2,353 | $399K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 824 | $392K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,261 | $383K |
| 96127 | <1% | 3,722 | $373K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 8,218 | $346K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 562 | $316K |
| 76830 | Ultrasound, transvaginal | <1% | 2,628 | $306K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 3,066 | $285K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,397 | $268K |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 1,524 | $260K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,241 | $239K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 15,018 | $237K |
| 36415 | Collection of venous blood by venipuncture | <1% | 102,076 | $231K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 24,792 | $199K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 8,303 | $198K |
| 93971 | <1% | 1,652 | $180K | |
| 43235 | <1% | 369 | $180K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 15,569 | $174K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,780 | $173K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 834 | $172K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,606 | $172K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,658 | $162K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,999 | $161K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,046 | $160K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 7,478 | $156K |
| 97162 | <1% | 3,502 | $147K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 323 | $147K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,666 | $146K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,294 | $140K |
| 76642 | <1% | 1,299 | $137K | |
| 97161 | <1% | 2,918 | $134K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 66,141 | $133K |
| 80061 | Lipid panel | <1% | 13,359 | $125K |
| 17110 | <1% | 287 | $124K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 906 | $120K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 148 | $117K |
| G0384 | Level 5 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 677 | $115K |
| 93017 | <1% | 991 | $114K | |
| 76536 | <1% | 994 | $113K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 15,447 | $112K |
| 10060 | <1% | 393 | $107K | |
| 12001 | <1% | 377 | $105K | |
| 76770 | <1% | 776 | $105K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 15,203 | $102K |
| G0380 | Level 1 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 652 | $102K |
| G0378 | Hospital observation service, per hour | <1% | 2,111 | $100K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 4,959 | $96K |
| 84484 | <1% | 16,919 | $94K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 521 | $91K |
| 90651 | <1% | 1,307 | $89K | |
| 71250 | <1% | 1,316 | $86K | |
| 70498 | <1% | 602 | $86K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 553 | $84K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 376 | $80K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 128 | $79K |
| 76801 | <1% | 1,101 | $76K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 4,006 | $75K |
| 96367 | <1% | 2,391 | $72K | |
| 97597 | <1% | 778 | $71K | |
| 85027 | <1% | 14,832 | $70K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 174 | $68K |
| 73630 | <1% | 4,932 | $68K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 974 | $66K |
| 73030 | <1% | 3,812 | $65K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,913 | $65K |
| 73110 | <1% | 4,141 | $64K | |
| 84439 | <1% | 6,884 | $62K | |
| 87040 | <1% | 7,211 | $61K | |
| 73610 | <1% | 4,128 | $59K | |
| 87631 | <1% | 726 | $59K | |
| 90715 | <1% | 2,858 | $57K | |
| 94060 | <1% | 1,247 | $57K | |
| 90686 | <1% | 5,013 | $57K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,662 | $55K |
| 73130 | <1% | 3,402 | $55K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,962 | $54K |
| 93246 | <1% | 784 | $53K | |
| 95806 | <1% | 96 | $52K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 7,517 | $52K |
| 86803 | <1% | 6,630 | $51K | |
| 73562 | <1% | 2,938 | $50K | |
| 72110 | <1% | 1,432 | $50K | |
| 96415 | <1% | 227 | $48K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 206 | $48K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 10,807 | $47K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 6,917 | $46K |
| 73564 | <1% | 2,462 | $45K | |
| 73502 | <1% | 2,358 | $45K | |
| 82607 | <1% | 4,042 | $44K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 12,782 | $41K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,109 | $41K |
| 70496 | <1% | 622 | $38K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,141 | $38K |
| 83605 | <1% | 8,139 | $38K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 7,939 | $36K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 5,469 | $36K |
| 72100 | <1% | 1,637 | $35K | |
| 84702 | <1% | 3,969 | $34K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 25,419 | $33K |
| 82728 | <1% | 4,176 | $33K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,185 | $33K |
| 86140 | <1% | 9,383 | $33K | |
| 29075 | <1% | 113 | $31K | |
| 72141 | <1% | 147 | $31K | |
| 96523 | <1% | 606 | $30K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,907 | $30K |
| 90714 | <1% | 1,234 | $28K | |
| 83880 | <1% | 4,672 | $26K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,167 | $26K |
| 74018 | <1% | 1,503 | $25K | |
| 87522 | Neg quan hep c or qual rna | <1% | 1,188 | $25K |
| 94729 | <1% | 1,197 | $25K | |
| 97750 | <1% | 1,346 | $24K | |
| 76870 | <1% | 183 | $24K | |
| 94726 | <1% | 1,038 | $24K | |
| 36591 | <1% | 3,721 | $23K | |
| 92523 | <1% | 187 | $23K | |
| 76882 | <1% | 280 | $23K | |
| 97113 | <1% | 784 | $22K | |
| 90670 | <1% | 3,336 | $22K | |
| 85379 | <1% | 3,394 | $22K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 176 | $22K |
| 12011 | <1% | 64 | $21K | |
| 87070 | <1% | 7,598 | $21K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 29 | $21K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,291 | $20K |
| 73080 | <1% | 1,492 | $20K | |
| 29125 | <1% | 63 | $19K | |
| 83550 | <1% | 3,812 | $18K | |
| 97116 | <1% | 1,336 | $18K | |
| 70486 | <1% | 343 | $18K | |
| 82105 | <1% | 1,253 | $18K | |
| 82570 | <1% | 3,859 | $18K | |
| 71045 | Radiologic examination, chest; single view | <1% | 12,072 | $17K |
| 73140 | <1% | 1,495 | $17K | |
| 94664 | <1% | 943 | $17K | |
| 84403 | <1% | 1,392 | $16K | |
| 86592 | <1% | 3,327 | $16K | |
| 72050 | <1% | 440 | $15K | |
| 84481 | <1% | 1,303 | $15K | |
| 77066 | Tomosynthesis, mammo | <1% | 435 | $15K |
| 85652 | <1% | 7,292 | $15K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 12,932 | $14K |
| 87340 | <1% | 3,155 | $14K | |
| 11721 | <1% | 638 | $14K | |
| 83540 | <1% | 4,051 | $14K | |
| 83735 | <1% | 7,647 | $14K | |
| 82677 | <1% | 529 | $14K | |
| 95813 | <1% | 38 | $14K | |
| 95886 | <1% | 1,012 | $13K | |
| 84153 | <1% | 1,596 | $13K | |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 148 | $12K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 103 | $12K |
| 87077 | <1% | 9,197 | $12K | |
| 82746 | <1% | 1,775 | $12K | |
| 74174 | <1% | 41 | $11K | |
| 99177 | <1% | 51 | $11K | |
| 81001 | <1% | 20,654 | $11K | |
| 82784 | <1% | 1,107 | $11K | |
| 0071A | <1% | 275 | $11K | |
| 73590 | <1% | 982 | $11K | |
| 93970 | <1% | 93 | $11K | |
| 90677 | <1% | 684 | $11K | |
| 86900 | <1% | 3,487 | $11K | |
| 73090 | <1% | 693 | $10K | |
| 97533 | <1% | 347 | $10K | |
| 0072A | <1% | 248 | $10K | |
| 64615 | <1% | 38 | $10K | |
| 86762 | <1% | 1,642 | $10K | |
| 83690 | <1% | 13,054 | $9K | |
| 80076 | <1% | 1,404 | $9K | |
| 98929 | <1% | 349 | $9K | |
| 87186 | <1% | 5,883 | $9K | |
| 99001 | <1% | 552 | $9K | |
| 85610 | <1% | 11,168 | $9K | |
| 80178 | <1% | 643 | $8K | |
| 72040 | <1% | 346 | $8K | |
| 77065 | Tomosynthesis, mammo | <1% | 207 | $8K |
| J7324 | Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose | <1% | 75 | $8K |
| 86038 | <1% | 1,470 | $8K | |
| 93296 | <1% | 487 | $8K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 329 | $8K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,298 | $8K |
| 83001 | <1% | 520 | $8K | |
| 97163 | <1% | 155 | $8K | |
| 86850 | <1% | 3,252 | $7K | |
| 90647 | <1% | 432 | $7K | |
| Q3014 | Telehealth originating site facility fee | <1% | 809 | $7K |
| 96368 | <1% | 697 | $7K | |
| 82043 | <1% | 2,190 | $7K | |
| 80305 | <1% | 3,098 | $7K | |
| 0296T | <1% | 446 | $7K | |
| 70491 | <1% | 37 | $7K | |
| 69209 | <1% | 393 | $6K | |
| 84146 | <1% | 382 | $6K | |
| 58300 | <1% | 37 | $6K | |
| 90734 | <1% | 785 | $6K | |
| 81003 | <1% | 10,986 | $6K | |
| 36430 | <1% | 82 | $6K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 391 | $6K |
| 97165 | <1% | 137 | $6K | |
| 82565 | <1% | 1,130 | $5K | |
| 97166 | <1% | 143 | $5K | |
| 84156 | <1% | 1,392 | $5K | |
| 87205 | <1% | 4,601 | $5K | |
| 86901 | <1% | 3,489 | $5K | |
| 0002A | <1% | 126 | $5K | |
| 82274 | <1% | 703 | $5K | |
| J3490 | Unclassified drugs | <1% | 663 | $5K |
| 72072 | <1% | 269 | $5K | |
| 0004A | <1% | 117 | $5K | |
| 97035 | <1% | 655 | $5K | |
| 0001A | <1% | 110 | $4K | |
| D0120 | Dental checkup, returning patient | <1% | 30 | $4K |
| 71271 | <1% | 40 | $4K | |
| 90707 | <1% | 999 | $4K | |
| 84703 | <1% | 5,183 | $4K | |
| 81025 | <1% | 7,554 | $4K | |
| 74019 | <1% | 175 | $4K | |
| 84550 | <1% | 1,440 | $4K | |
| 87210 | <1% | 2,165 | $3K | |
| 83970 | <1% | 134 | $3K | |
| 83516 | <1% | 659 | $3K | |
| 84100 | <1% | 1,532 | $3K | |
| 86704 | <1% | 593 | $3K | |
| 84402 | <1% | 216 | $3K | |
| 51798 | <1% | 1,211 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,766 | $3K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 180 | $3K |
| 82550 | <1% | 1,647 | $3K | |
| 86706 | <1% | 546 | $3K | |
| 90732 | <1% | 201 | $3K | |
| 90480 | <1% | 101 | $2K | |
| 86336 | <1% | 497 | $2K | |
| 86593 | <1% | 401 | $2K | |
| 85018 | <1% | 3,753 | $2K | |
| 94770 | <1% | 12 | $2K | |
| 87147 | <1% | 1,147 | $2K | |
| 72131 | <1% | 53 | $2K | |
| 77336 | <1% | 28 | $2K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 16 | $2K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,941 | $2K |
| 86364 | <1% | 353 | $2K | |
| 90688 | <1% | 714 | $2K | |
| 86431 | <1% | 366 | $2K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 29 | $2K |
| 77080 | <1% | 13 | $1K | |
| 82950 | <1% | 284 | $1K | |
| 0297T | <1% | 57 | $1K | |
| 86430 | <1% | 286 | $1K | |
| 74022 | <1% | 76 | $1K | |
| 85730 | <1% | 3,095 | $1K | |
| 85014 | <1% | 695 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 12,296 | $1K |
| 71101 | <1% | 94 | $1K | |
| 86376 | <1% | 76 | $1K | |
| 82803 | <1% | 2,294 | $1K | |
| 0074A | <1% | 32 | $1K | |
| 87081 | <1% | 372 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 104 | $1K |
| 72170 | <1% | 94 | $1K | |
| 80164 | <1% | 89 | $995.16 | |
| 90656 | <1% | 220 | $941.85 | |
| 87480 | <1% | 260 | $939.64 | |
| 82785 | <1% | 56 | $930.87 | |
| 83615 | <1% | 551 | $928.11 | |
| 82670 | <1% | 73 | $916.94 | |
| 82140 | <1% | 283 | $785.63 | |
| 87045 | <1% | 140 | $652.30 | |
| 88720 | <1% | 2,572 | $604.80 | |
| 87660 | <1% | 258 | $530.23 | |
| 87510 | <1% | 260 | $526.25 | |
| 86200 | <1% | 64 | $525.82 | |
| 96381 | <1% | 97 | $515.35 | |
| 80050 | General health panel | <1% | 98 | $506.58 |
| 0081A | <1% | 13 | $500.00 | |
| 87493 | <1% | 108 | $455.47 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 410 | $439.71 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 881 | $438.97 |
| Q2038 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | <1% | 18 | $434.17 |
| 73000 | <1% | 18 | $427.50 | |
| 73560 | <1% | 31 | $393.35 | |
| 87899 | <1% | 157 | $377.52 | |
| 83721 | <1% | 52 | $376.56 | |
| 86003 | <1% | 43 | $369.47 | |
| 83002 | <1% | 28 | $350.16 | |
| 87046 | <1% | 139 | $328.33 | |
| 86308 | <1% | 227 | $325.71 | |
| 86480 | <1% | 13 | $322.23 | |
| 76000 | <1% | 163 | $301.03 | |
| 96376 | <1% | 4,441 | $296.62 | |
| 82533 | <1% | 45 | $280.45 | |
| 87338 | <1% | 39 | $276.59 | |
| 84480 | <1% | 26 | $270.12 | |
| 86695 | <1% | 13 | $259.10 | |
| 84436 | <1% | 30 | $251.07 | |
| 73552 | <1% | 28 | $233.97 | |
| 88304 | <1% | 162 | $231.50 | |
| 51702 | <1% | 160 | $230.69 | |
| 82947 | <1% | 55 | $184.04 | |
| 84112 | <1% | 14 | $182.50 | |
| 82977 | <1% | 45 | $175.58 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,103 | $175.00 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 945 | $173.57 |
| 82150 | <1% | 43 | $166.49 | |
| 80177 | <1% | 15 | $163.19 | |
| 87209 | <1% | 14 | $153.57 | |
| 84165 | <1% | 31 | $152.99 | |
| 83655 | <1% | 54 | $136.09 | |
| 90648 | <1% | 1,755 | $131.36 | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 1,490 | $113.38 |
| 86800 | <1% | 12 | $107.31 | |
| 82248 | <1% | 16 | $105.62 | |
| 87177 | <1% | 14 | $94.31 | |
| 86696 | <1% | 15 | $85.93 | |
| 84145 | <1% | 310 | $71.93 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,092 | $68.94 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 56 | $63.52 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,488 | $58.40 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,733 | $56.62 |
| A9270 | Non-covered item or service | <1% | 15,986 | $54.50 |
| 85007 | <1% | 12 | $54.16 | |
| 82010 | <1% | 271 | $53.90 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 2,909 | $52.42 |
| 81002 | <1% | 810 | $49.93 | |
| 88312 | <1% | 56 | $48.86 | |
| 86787 | <1% | 12 | $48.41 | |
| G0008 | Administration of influenza virus vaccine | <1% | 453 | $44.73 |
| 90473 | <1% | 2,007 | $43.32 | |
| 84520 | <1% | 12 | $41.89 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,287 | $40.62 |
| 87329 | <1% | 12 | $35.18 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,234 | $29.71 |
| 36416 | <1% | 1,563 | $29.20 | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,054 | $29.16 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,149 | $27.08 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,741 | $25.42 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,710 | $18.56 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 664 | $18.42 |
| 88342 | <1% | 28 | $18.32 | |
| 87075 | <1% | 68 | $17.13 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,359 | $15.03 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,085 | $13.09 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 93 | $12.04 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 400 | $11.32 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 258 | $10.93 |
| 90680 | <1% | 2,382 | $10.85 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 744 | $10.64 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 713 | $9.94 |
| 82077 | <1% | 60 | $9.33 | |
| 90723 | <1% | 1,519 | $9.09 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,809 | $6.91 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,144 | $3.63 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,020 | $3.42 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,248 | $3.32 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,032 | $2.91 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 124 | $2.68 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 802 | $0.66 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,173 | $0.46 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 16,844 | $0.01 |
| 90716 | 0% | 844 | $0.00 | |
| 90697 | 0% | 300 | $0.00 | |
| 90698 | 0% | 1,033 | $0.00 | |
| 90696 | 0% | 848 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 507 | $0.00 |
| 90619 | 0% | 390 | $0.00 | |
| 82962 | 0% | 27 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 197 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 74 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 186 | $0.00 |
| 90474 | 0% | 195 | $0.00 | |
| 90744 | 0% | 84 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 535 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 179 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 21 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 162 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 14 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 128 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 205 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 186 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 93 | $0.00 |
| 94760 | 0% | 69 | $0.00 | |
| 72128 | 0% | 12 | $0.00 | |
| J1815 | Injection, insulin, per 5 units | 0% | 295 | $0.00 |
| D9999 | Unspecified adjunctive procedure, by report | 0% | 29 | $0.00 |
| 90674 | 0% | 14 | $0.00 | |
| 90381 | 0% | 14 | $0.00 | |
| 90710 | 0% | 1,075 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 731 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 57 | $0.00 |
| 90633 | 0% | 2,276 | $0.00 | |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 13 | $0.00 |
| 90700 | 0% | 961 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 578 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 386 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 36 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 1,242 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 356 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 246 | $0.00 |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | 0% | 693 | $0.00 |
| 93356 | 0% | 212 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 299 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 211 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 42 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 13 | $0.00 |
| 96417 | 0% | 18 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 155 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 16 | $0.00 |
| 99173 | 0% | 32 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 54 | $0.00 |
| A4649 | Surgical supply; miscellaneous | 0% | 18 | $0.00 |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 27 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGREGSON, CHARLES (INTERIM CEO)
| Provider | Location | Paid |
|---|---|---|
| Olympic Medical Physicians | Port Angeles, WA | $7.77M |
| Clallam County Public Hospital District 2 | Port Angeles, WA | $573K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.